Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.9092
Revised: October 19, 2013
Accepted: November 3, 2013
Published online: December 21, 2013
Core tip: The combination therapy with ZD6126 and thalidomide significantly delayed liver tumor growth due to synergistic effects by inducing cumulative tumor necrosis in rodents. The apparent diffusion coefficient (ADC)high performed significantly better than ADCall for the monitoring of tumor necrosis on day 2. The ADCperf could better reflect the reduction of blood flow due to the vessel shutdown induced by ZD6126, compared to the ADClow. The ADCperf could provide valuable perfusion information from diffusion weighted magnetic resonance imaging data.